Background {#Sec1}
==========

Eosinophilic pneumonia is a rare, but serious respiratory syndrome that occurs when eosinophils accumulate in the lungs \[[@CR1], [@CR2]\]. It has been associated with several medications and chemicals, with antibiotics and nonsteroidal anti-inflammatory drugs among the most common \[[@CR3], [@CR4]\].

The pathophysiology of acute eosinophilic pneumonia is thought to be caused by detection of an antigen by alveolar macrophages which leads to recruitment of T-helper 2 lymphocytes and subsequent release of interleukin 5. Interleukin 5 promotes eosinophil production and migration to the lung. Additionally, eotaxin (a potent eosinophil chemoattractant) production by alveolar macrophages, pulmonary endothelial cells, airway smooth muscle cells, and alveolar epithelial cells leads to further accumulation of eosinophils in the lungs \[[@CR5]\].

Daptomycin is a cyclic lipopeptide antibiotic derived from the fermentation of *Streptomyces roseosporus*. Daptomycin has activity against Gram-positive organisms including methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci (VRE) \[[@CR6]\]. In 2007, pulmonary eosinophilia was added to the "Adverse Reactions, Post-Marketing Experience" section of the product label for daptomycin \[[@CR2]\]. A review of the literature and the US FDA Adverse Event Reporting System database in 2012 revealed 7 definite, 13 probable, and 38 possible cases of daptomycin-induced eosinophilic pneumonia \[[@CR1]\]. While the mechanism of daptomycin's pulmonary toxicity is not known, the drug undergoes conformational change through interaction with calcium which allows binding to the cytoplasmic membrane, increased membrane permeability, and intracellular ion escape \[[@CR7]\]. The antibacterial activity of daptomycin is decreased because of its binding to pulmonary surfactant. Some have speculated two potential mechanisms for daptomycin's pulmonary toxicity: 1) chronic daptomycin administration results in drug accumulation near the epithelial alveolar surface causing epithelial injury and pneumonia and 2) the daptomycin-surfactant interaction could alter lipid integrity which may stimulate an inflammatory response \[[@CR3], [@CR7], [@CR8]\].

Per the FDA guidance, eosinophilic pneumonia is attributed to daptomycin when the following criteria are met: 1) concurrent exposure to daptomycin, 2) fever, 3) dyspnea with increased oxygen requirement or requiring mechanical ventilation, 4) new infiltrates on chest x-ray or computed tomography (CT) scan, 5) bronchoalveolar lavage (BAL) with \> 25% eosinophils, and 6) clinical improvement following daptomycin withdrawal \[[@CR2]\]. Solomon and Schwartz \[[@CR4]\] have also developed criteria for drug- or toxin-induced eosinophilic pneumonia that is similar and includes 1) presence of simple, acute, or chronic eosinophilic pneumonia by diagnostic criteria which includes excess of eosinophils either on lung biopsy or BAL (usually ≥25%) in the setting of parenchymal infiltrates 2) presence of a potential candidate drug or toxin in an appropriate time frame 3) no other cause of eosinophilic pneumonia such as fungal or parasitic infection 4) clinical improvement after cessation of the drug or toxin, and 5) recurrence of eosinophilic pneumonia with re-challenge to the drug or toxin. However, re-challenge is often not recommended as it can be dangerous \[[@CR4], [@CR5]\].

Although the mechanism of daptomycin-induced eosinophilic pneumonia is unknown, some have speculated that daptomycin may bind to human surfactant and accumulate in the alveolar space causing injury to the epithelium with resulting inflammation \[[@CR7], [@CR8]\]. The purpose of this review is to systematically evaluate the published literature describing daptomycin-induced eosinophilic pneumonia.

Methods {#Sec2}
=======

All relevant cases and studies were identified by systematically searching of the PubMed, EMBASE, Google Scholar, Cochrane Database of Systematic Reviews, and Clin-Alert databases by two reviewers from inception through May 2016. The truncated terms "daptomycin", "eosinophil\*", and "pneumon\*" were searched in each database. All case reports that included information regarding patient age, indication, clinical and objective findings, treatment, and outcome were evaluated. Reports not published in English were excluded as well as abstracts from conference proceedings. Descriptive analysis was used to present pooled demographic information and other data where applicable.

Results {#Sec3}
=======

No clinical or observational trials assess daptomycin-induced eosinophilic pneumonia; only case reports and case series are published. In 2012, Kim et al. identified 7 definite, 13 probable, and 38 possible cases of daptomycin-induced eosinophilic pneumonia via review of literature and FDA Adverse Event Reporting System Reports (AERS) as defined in Table [1](#Tab1){ref-type="table"} \[[@CR1]\]. Details regarding the 38 possible cases reported through AERS were not described. Of the 20 cases that were identified as definite or probable, 9 have been published in the literature, the remaining 11 were summarized by Kim \[[@CR1], [@CR3], [@CR9]--[@CR13]\]. We also identified 39 additional cases of eosinophilic pneumonia attributed to daptomycin for a total of 59 cases described in the literature \[[@CR7], [@CR14]--[@CR24]\]. Of those, 21 were excluded from this systematic review because they were abstract presentations at international meetings and did not go through the peer review publishing process \[[@CR25]--[@CR41]\]. Another three were excluded because they were not published in English \[[@CR42]--[@CR44]\]. Currently available data on a total of 35 cases of daptomycin-induced eosinophilic pneumonia is summarized in Table [2](#Tab2){ref-type="table"}.Table 1Criteria for inclusion as definite, probably, possible, and unlikely cases of daptomycin-induced eosinophilic pneumonia \[[@CR1], [@CR2]\]DefiniteProbablePossibleUnlikelyConcurrent exposure to daptomycinConcurrent exposure to daptomycinConcurrent exposure to daptomycinAll other cases that did not meet criteriaDyspnea with increased oxygen requirement or requiring mechanical ventilationDyspnea with increased oxygen requirement or requiring mechanical ventilationNew infiltrates on CXR or CTNew infiltrates on CXR or CTNew infiltrates on chest x-ray or CTClinical improvement following daptomycin withdrawal OR the patient diedBAL with \> 25% eosinophilsBAL with ≤ 25% eosinophils OR peripheral eosinophiliaClinical improvement following daptomycin withdrawalClinical improvement following daptomycin withdrawalFeverAdapted from references 1 and 2Abbreviation: *BAL* bronchoalveolar lavage; *CT* computed tomography; *CXR* chest x-ray Table 2Summary of 35 cases of presumed daptomycin-induced eosinophilic pneumoniaCaseAge/SexIndicationDose (mg/kg/day)DAP Duration (wks)Clinical FindingsObjective FindingsTreatmentOutcomeKim \[[@CR1]\] (2012)63/FMSSA spinal osteomyelitis63• Fever\
• Cough, hypoxemia• BAL = 60--70%\
• Peripheral eosinophilia\
• Elevated CPK• DAP d/c\
• CorticosteroidsRecovered64/MOsteomyelitis with bacteremia5.74• Fever\
• Dyspnea, hypoxia• BAL = 44%\
• Peripheral eosinophilia\
• Pulmonary infiltrates• DAP d/cRecovered79/MEndocarditis66• Fever, cough, night sweats\
• Dyspnea requiring MV• BAL = 9--13%\
• Peripheral eosinophilia\
• CT = ground glass opacities\
• Lung biopsy = eosinophilic pneumonitis• DAP d/c\
• CorticosteroidsImproved26/MMRSA bacteremia7.351.4• Dyspnea requiring MV• BAL not performed\
• Peripheral eosinophilia\
• Pulmonary infiltrates\
• Eosinophils in tracheal aspirate• DAP d/cImproved43/MMRSA osteomyelitis61--2• Pleuritic pain\
• Hypoxia requiring O~2~• BAL not performed\
• Peripheral eosinophilia\
• CT = bilateral infiltrates• DAP d/c\
• Given NSAIDs, meperidine• Improved\
• Residual infiltrates on CT s/p 4 wks66/MMSSA bacteremia61• Dyspnea requiring O~2~\
• Hematemesis• BAL with eosinophils (not quantified)\
• Peripheral eosinophilia• DAP d/c\
• CorticosteroidsRecovered71/MMRSA diabetic foot infection47.7• Dyspnea requiring O~2~• Peripheral eosinophilia\
• Elevated CRP\
• Elevated ESR\
• CT = bilateral interstitial opacities• DAP d/cImproved77/FBacteremia (enterococcal)51• Dyspnea requiring O~2~• Peripheral eosinophilia\
• CXR = pneumonitis• DAP d/c\
• CorticosteroidsImproved67/MMRSA endocarditis64.3• Dyspnea requiring MV• BAL = 9%\
• Peripheral eosinophilia\
• CT = bilateral pulmonary infiltrates• DAP d/c\
• CorticosteroidsImproved73/MProsthetic joint infection53.7• Fever\
• Dyspnea requiring MV• Peripheral eosinophilia\
• CT = bilateral ground glass appearance• DAP d/c\
• CorticosteroidsRecovered81/FMRSA paraspinal abscess61.6• Dyspnea requiring MV• BAL = 2% (s/p corticosteroid)^a^\
• CXR = bilateral mid-lung infiltrates• DAP d/c\
• CorticosteroidsImprovedCobb \[[@CR6]\] (2007)84/MInfection of left knee prosthesis44• Decreased appetite\
• Weight loss\
• Fatigue\
• Weakness• Elevated ESR\
• CT with infiltrates\
• Lung biopsy = eosinophilic pneumonia• DAP d/c• Improved within 2 weeksHayes \[[@CR7]\] (2007)60/MMSSA endocarditisNR2• Fever, rigors, diaphoresis\
• Required MV• BAL 16% initially\
• BAL 26% after rechallenge\
• CRP elevated• DAP d/c -- then re-challenged\
• DAP d/c plus corticosteroids• Rechallenge failed within 4 h\
• Improved within 24 h after DAP d/cKakish \[[@CR8]\] (2008)65/MMRSA vertebral osteomyelitis, epidural abscess62• Low-grade fever\
• Dyspnea requiring MV• BAL = 33%\
• Peripheral eosinophilia\
• Lung biopsy revealed eosinophils• DAP d/c\
• Corticosteroids• Improved within 72 h\
• Normal CT at 3 monthsShinde \[[@CR9]\] (2009)54/MComplicated inguinal hernia repairNR2• Low grade fever, cough\
• Hypoxemia requiring MV• Peripheral eosinophilia\
• CT = bilateral airspace, peripheral predominance, small bilateral effusions\
• Lung biopsy = many eosinophils• DAP d/c\
• Corticosteroids• Improved within 24 h\
• Normal CT at 4 weeksLal \[[@CR10]\] (2010)82/MProsthetic joint infectionNR3• Fever\
• Hypoxia requiring O~2~• BAL = 14%\
• Peripheral eosinophilia\
• CT = patchy bilateral infiltrates• DAP d/c\
• Corticosteroids• Recovered after 5 days\
• Recurrent symptoms\
• Low dose steroids required87/MProsthetic knee infectionNR4• Dyspnea, dry cough requiring O~2~\
• Malaise, chills, anorexia, fever• BAL = 40%\
• Peripheral eosinophilia\
• CT = bilateral patchy pulmonary infiltrates• DAP d/c\
• Corticosteroids• Recurrence s/p steroid taper\
• Low dose steroids for 2 yearsMiller \[[@CR11]\] (2010)60/MMSSA prosthetic hip infection62• Cough, fever\
• Hypoxia requiring O~2~• BAL = 81% after rechallenge\
• Peripheral eosinophilia\
• CT = bilateral scattered ground-glass opacities\
• Lung biopsy = acute fibrinous and organizing pneumonia, reactive alveolar and interstitial epithelial changes• DAP d/c\
• Rechallenged, DAP d/c\
• Corticosteroids• Improved within 48 h\
• Rechallenge failed within 24 h60/MMRSA osteomyelitis, septic arthritis62• Non-productive cough, dyspnea\
• Low-grade fevers, chills• Peripheral eosinophilia\
• CT = patchy peripheral nodular/ground-glass• DAP d/c• Resolution within 96 h\
• Recurrence with re-challenge at 5 months83/MDiskitis of lumbar spine64• Progressive dyspnea,\
• Cough, pleuritic chest pain• BAL = 13%\
• Peripheral eosinophilia\
• CT = diffuse ground-glass, reticular opacities\
• Lung biopsy = acute organizing pneumonia, eosinophilia, chronic inflammation, fibro-inflammatory changes• DAP d/c\
• CorticosteroidsImproved within 6 daysKalogeropoulous \[[@CR12]\] (2011)78/MEndocarditis81.4• Fever, chills, diaphoresis,\
• Hypoxemia requiring O~2~• BAL = 27.5%\
• Peripheral eosinophilia\
• Elevated ESR\
• Elevated CRP\
• CT = patchy consolidation, ground-glass opacities, bilateral pleural effusions• DAP d/cResolution within 24 hRether \[[@CR13]\] (2011)69/MSpondylo-discitis with lumbar epidural and bilateral psoas abscesses63• Fever\
• Dyspnea requiring O~2~• BAL = 30%\
• Elevated CRP\
• CXR = extensive patchy infiltrates in RLL and entire left lung• DAP d/c\
• CorticosteroidsImproved within 24 hPatel \[[@CR14]\] (2014)61/FOsteomyelitisNR1• Dry cough\
• Dyspnea requiring MV• BAL = 30%\
• Peripheral eosinophilia\
• CT = bilateral pleural effusion, diffuse bilateral patchy infiltrate• DAP d/c\
• CorticosteroidsImproved within 72 hPhillips \[[@CR15]\] 2014)48/MOsteomyelitis63• Fever\
• Dyspnea requiring MV• BAL = 17%\
• Peripheral eosinophilia\
• CXR = patchy bilateral airspace opacities• DAP d/c\
• Corticosteroids• Improved28/MOsteomyelitis64• Dyspnea requiring MV\
• Chest pain, light-headedness• BAL = 74%\
• Peripheral eosinophilia\
• CT = diffuse multi-lobar infiltrates• DAP d/c\
• CorticosteroidsResolution within 1 weekYamamoto \[[@CR16]\] (2014)82/MMRSA bacteremia102• Low grade fever\
• Hypoxia• CT = bilateral ground glass opacities\
• Sputum negative for eosinophils• DAP d/cImprovedYusuf \[[@CR17]\] (2014)64/MProsthetic joint infection104• Fever• BAL = 47%\
• Peripheral eosinophilia\
• Elevated CRP\
• CT = diffuse bilateral ground-glass opacities• DAP d/cImproved within 24 h61/MProsthetic joint infection102• Fever\
• Dyspnea requiring MV• BAL = 3%\
• Peripheral eosinophilia\
• Elevated CRP\
• CT = ground-glass consolidation, bilateral pleural effusion• DAP d/cImproved within 24 hChiu \[[@CR18]\] (2015)77/MOsteomyelitis66• Pleuritic chest pain\
• Cough, dyspnea requiring O~2~• BAL = 18%\
• Elevated CRP\
• CXR = diffuse bilateral airspace disease• DAP was d/c 1 day before symptoms\
• CorticosteroidsImproved within 60 h74/FInfected hip reconstruction61^b^• Fever\
• Dyspnea requiring O~2~• CXR -- bilateral airspace disease• DAP d/c\
• CorticosteroidsImproved within 24 hHagiya \[[@CR19]\] (2015)34/MEndocarditis101• Cough with mild hypoxemia• Peripheral eosinophilia\
• Elevated CRP\
• CT = consolidation in peripheral field of right upper lobe• DAP d/cResolved within 6 weeksHatipoglu \[[@CR20]\] (2015)67/FMRSA diabetic foot ulcerNR^c^3.3• Cough, dyspnea requiring BPAP\
• Fever, fatigue, decreased appetite• Peripheral eosinophilia\
• Elevated CRP\
• CT = right lobe infiltration• DAP d/c\
• Inhaled corticosteroidsImproved within 72 hRoux \[[@CR21]\] (2015)67/MMSSA prosthetic hip infection62.4• Dry cough, hypoxemia• BAL = 10%\
• Peripheral eosinophilia\
• CT = diffuse alveolar and interstitial opacities• DAP d/c\
• CorticosteroidsImproved within 96 hWojtaszczyk \[[@CR22]\] (2015)76/MSeptic arthritis and pacemaker vegetationNR2• Dyspnea requiring O~2~, cough\
• Fever, fatigue• BAL = 58%\
• Elevated CRP\
• CT = bilateral ground glass opacity, patchy consolidation• DAP d/c\
• CorticosteroidsResolved within 72 hAkcaer \[[@CR23]\] (2016)60/MMSSA post-amputation abscess53.4• Tachypnea, hypoxia requiring O~2~• Peripheral eosinophilia\
• Elevated CRP\
• Elevated ESR\
• HRCT = right pleural effusion, bilateral tree-in-bud pattern, bilateral scattered ground-glass opacities• DAP d/cResolved within 72 hKEY: *BAL* bronchoalveolar lavage, *BPAP* bilevel positive airway, *CPK* creatine phosphokinase, *CRP* C-reactive protein, *CT* computed tomography scan, *CXR* chest x-ray, *DAP* daptomycin, *d/c* discontinued, *ESR* erythrocyte sedimentation rate, *F* female, *HRCT* high resolution computed tomography, *M* male, *MRSA* methicillin resistant *Staphylococcus aureus*, *MSSA* methicillin susceptible *Staphylococcus aureus, MV* mechanical ventilation, *NR* not reported, *NSAID* nonsteroidal anti-inflammatory drug*, O* ~*2*~ oxygen, *RLL* right lower lobe; *s/p* status post, *wks* weeks^a^ = DAP given for 1 week, then held for 2 weeks, and restarted. Symptom onset in 72 h after restarting, ^b^ = not included in analysis, ^c^ = DAP 500 mg/day given (dose mg/kg unknown)

Analysis of the 35 cases shows eosinophilic pneumonia resulting from daptomycin use is most likely to be reported in males with a mean age of 65.4 ± 15 years and a mean length of therapy of 2.8 ± 1.6 weeks at symptom onset. The most common indication for daptomycin use was osteomyelitis and/or diabetic foot infection closely followed by prosthetic joint infection. Daptomycin dose ranged from 4 to 10 mg/kg/day depending on renal function; therefore, the adverse effect does not appear to be dose dependent, but time dependent exposure. The most common symptoms of eosinophilic pneumonia included fever and dyspnea often requiring either oxygen supplementation or mechanical ventilation. Other clinical findings included malaise, elevated ESR (4/35 cases), or elevated C-reactive protein (11/35 cases). Peripheral eosinophilia was also present in approximately 77% (27/35 cases) of patients. Many cases also had computed tomography scans or chest x-rays which revealed opacities (12/35 cases) and bilateral infiltrates (13/35 cases). Symptom improvement was seen within 24 h through one week after daptomycin discontinuation. The majority of patients were also prescribed treatment with corticosteroids (23/35 cases); however, all patients were reported to recover (See Table [3](#Tab3){ref-type="table"}).Table 3Compilation of available data on 35 cases of daptomycin-induced eosinophilic pneumoniaSex, n (%)Male29 (83)Female6 (17)Age(years), mean ± SD65.4 ± 15Daptomycin indication, n (%)Osteomyelitis/diabetic foot infection11 (31)Prosthetic joint infection9 (26)Endocarditis5 (14)Bacteremia4 (11)Abscess3 (9)Other3 (9)Daptomycin dose (mg/kg/day), mean ± SD6.4 ± 1.6Treatment duration at symptom onset (weeks), mean ± SD2.8 ± 1.6Clinical findings, n (%)Dyspnea33 (94)Fever20 (57)Cough13 (37)Requiring oxygen15 (43)Requiring mechanical ventilation12 (34)Infiltrates/opacities of CT/CXR, n (%)30 (86)BAL eosinophils %, mean ± SD32 ± 22.4Peripheral eosinophilia, n (%)27 (77)Lung biopsy consistent with AEP, n (%)6 (17)Treatment, n (%)Daptomycin discontinued only12 (34)Daptomycin discontinued plus corticosteroid23 (66)*AEP* acute eosinophilic pneumonia, *BAL* bronchoalveolar lavage, *CT* computed tomography, *CXR* chest x-ray, *SD* standard deviation

Discussion {#Sec4}
==========

While the criteria developed by Solomon and Schwartz differ from the FDA guidance, they are largely similar in that an offending agent (here, daptomycin) must be present, \>25% eosinophils are present, and that clinical improvement is seen after discontinuation of the drug. The FDA guidance also includes some measures of symptomatology such as fever and dyspnea \[[@CR2], [@CR4]\].

Overall, dyspnea was the most common documented symptom associated with eosinophilic pneumonia followed by the presence of either pulmonary infiltrates or opacities on chest x-ray or CT. A total of 10 cases specifically mentioned the characteristic finding of ground glass opacities on CT. A potential limitation of this review is that some of the daptomycin-induced eosinophilic pneumonia used lung biopsy in place of BAL as part of the diagnostic criteria which is not part of the FDA guidance, but is included in the Solomon and Schwartz criteria. In addition, since some patients had BAL \< 25% eosinophils but lung biopsy revealed eosinophilia \[[@CR1], [@CR13]\], a 25% cut off may be too strict in certain situations.

Corticosteroids are believed to be beneficial at halting clinical manifestations of daptomycin-induced eosinophilic pneumonia and were used in the majority of reported cases. Steroids exert action through eosinophilic apoptosis and through accelerating intracellular signaling involved in eosinophil death \[[@CR45]\]. No dose or length of corticosteroid treatment is established in guidelines for eosinophilic pneumonia; however, a commonly employed regimen is intravenous methylprednisolone 60--125 mg every 6 h, with conversion to prednisone 40--60 mg oral daily and taper over 2--6 weeks. Use of a 2- or 4-week course appears to have similar time to resolution of clinical symptoms and radiological abnormalities \[[@CR46]\].

Conclusion {#Sec5}
==========

As use of daptomycin continues to increase, it is important for clinicians to recognize and appropriately manage daptomycin-induced eosinophilic pneumonia. Although symptoms may resolve upon discontinuation of daptomycin, use of corticosteroid may be beneficial for recovery. Further research is needed to determine the exact mechanism of daptomycin-induced eosinophilic pneumonia and identify the optimal treatment course.
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FDA

:   Food and Drug Administration

MRSA

:   Methicillin resistant Staphylococcus aureus

VRE
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